Partial-Methylated HeyL Promoter Predicts the Severe Illness in Egyptian COVID-19 Patients
Table 2
Correlation between methylation status of the promoter of HeyL gene and clinical-pathological features in COVID-19 patients.
Clinical-pathological characteristic features
Partial-methylated ()
Unmethylated ()
Odd Ratio (OR)
95% CI
value
Sex
Male (%)
14 (63.6)
5 (62.5)
1.05
0.1968-5.6021
0.057
0.9545
Female(%)
8 (36.3)
3 (37.5)
Age
(≥50)(%)
17 (77.2)
2 (25)
10.20
1.5478-67.2189
2.414
0.0158
(<50)(%)
5 (22.7)
6 (75)
Fever (>38.5°C) (%)
20 (90.9)
4 (50)
10.00
1.3420-74.5140
2.247
0.0246
Fever (37°C-38.5°C)(%)
2 (9.09)
4 (50)
Severe pneumonia (%)
17 (77.2)
3 (37.5)
5.66
0.9902-32.4293
1.949
0.0513
Mild/moderate pneumonia (%)
5 (22.7)
5 (62.5)
Anosmia/ageusia (%)
18 (81.8)
3 (37.5)
7.50
1.2457-45.1542
2.200
0.0278
No anosmia/ageusia (%)
4 (18.2)
5 (62.5)
Pulmonary embolism (%)
7 (31.8)
0 (0)
8.23
0.4168-162.351
1.38
0.1661
No embolism (%)
15 (68.2)
8 (100)
Dry cough (%)
19 (86.3)
3 (37.5)
10.55
1.6119-69.1239
2.458
0.0140
Mucous (%)
3 (13.6)
5 (62.5)
No diarrhea (%)
10 (45.4)
4 (50)
0.83
0.1649-4.2118
0.221
0.8254
Diarrhea (%)
12 (54.5)
4 (50)
ICU admission (%)
8 (36.3)
2 (25)
1.714
0.2775-10.5898
0.580
0.5618
No ICU admission (%)
14 (63.6)
6 (75)
A standard normal deviate (-value) is calculated as ln(OR)/SE{ln(OR)}. CI: confidence interval. value for comparing between the clinical pathological findings and routine biomarkers of COVID-19 patients regarding to the methylation status; partial-methylated and unmethylated HeyL promoter. Statistically significant at .
